Response and adverse drug reactions to combination chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma: Comparison of CHOP, COP-BLAM, COP-BLAM III, and THP-COPBLM

European Journal of Haematology

Volumn 63, Issue 5, 1999, Pages 337-344

  Niitsu, Nozomi ^a   Umeda, Masanori ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CHOP regimen; COP BLAM regimen; Elderly; Non Hodgkin's lymphoma; THP COPBLM regimen

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PIRARUBICIN; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCORING SYSTEM; STOMATITIS;

EID: 0032728534     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1999.tb01137.x     Document Type: Article

References (22)

1. 1. SHIPP MA. International non-Hodgkin's lymphoma prognostic factors project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
2. 2. NIITSU N. Prognostic factors in elderly patients with non-Hodgkin's lymphoma treated with cyclophosphamide, vincristine, prednisolone, bleomycin, adriamycin and procarbazine (COP-BLAM) therapy. Acta Haematol 1997;198:130-135.
3. 3. FENTIMAN IS. Treatment of cancer in the elderly. Br J Cancer 1991;64:993-995.
4. 4. DIXON DO, NEILAN B, JONES SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma. J Clin Oncol 1986;4:295-305.
5. 5. VOSE JM, ARMITAGE JO, WEISENBURGER DD, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988;6:1838-1844.
6. 6. FISHER RI, GAYNOR ER, DAHLBERG S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006.
7. 7. CARBONE PP, KAPLAN HS, MUSSHOF K, SMITHERS DW, TUBIANA M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971;31:1860-1861.
8. 8. NIITSU N, UMEDA M. THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for non-Hodgkin's lymphoma in elderly patients: a prospective study. Leukemia 1997;11:1817-1820.
9. 123I-MIBG myocardial SPECT in patients with adriamycin-induced cardiomyopathy. Nucl Med 1994;31:1051-1057.
10. 10. LISTER TA, CROWTHER D, SUTCLIFFE SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-1636.
11. 11. KAPLAN EL, MEIER P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481.
12. 12. World Health Organization, WHO handbook for reporting results of cancer treatment. Geneva, Switzerland: WHO, 1979.
13. 13. HRYNIUK WM, BUSH H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281-1288.
14. 14. WEISENBURGER DD. Epidemiology of non-Hodgkin's lymphoma:Recent findings regarding an emergic epidemic. Ann Oncol 1994;5:19-24(suppl).
15. 15. GREINER TC, MEDEIROS LJ, JAFFE ES. Non-Hodgkin's lymphoma. Cancer 1995;75:370-380.
16. 16. COLEMAN M, ARMITAGE JO, GAYNOE M, et al. The COPBLAM programs: evolving chemotherapy concepts in large cell lymphoma. Semin Hematol 1988;25:23-33.
17. 17. BASTION Y, BLAY JY, DIVINE M, et al. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival-A groupe d'Etude des lymphomas de l'Adulte study on 453 patients older than 69 years. J Clin Oncol 1997;15:2945-2953.
18. 18. SONNEVELD P, DE RIDDER M, VAN DER LELIE H, et al. Comparison 18 of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995;13:2530-2539.
19. 131I]-iodobenzylguanidine. J Nucl Med 1980;21:349-353.
20. 20. STRAUSS HW, YASUDA T, GOLD HK, et al. Potential role of combined fatty acid and thallium imaging in patients with myocardial ischemia and infarction. J Nucl Med 1987;28:632.
21. 21. NIITSU N, YAMAZAKI J, SATO M, et al. Cardiotoxicity of combined administration of adriamycin and recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats with special reference to 125I-MIBG cardioautoradiography and histopathological findings. In Vivo 1995;9: 455-462.
22. 22. WAKASUGI S, FISCHMAN AJ, BAHICH JW, et al. Metaiodobenzylguanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy. J Nucl Med 1993;34:1282-1286.